Hybrid cooperative complex treatment is associated with reduced facial pore size in a pilot study Authors: Erik Koppert, Roya Zarmehr Zamin, Suyeon Lee, Kyu-Ho Yi Published: 2026 ABSTRACT AbstractEnlarged facial pores are a common aesthetic concern associated with aging and reduced dermal support. Hybrid Cooperative Complex (HCC), a stabilized hyaluronic acid formulation, has been proposed to improve skin quality through bioremodeling. This prospective observational pilot study evaluated changes in facial pore size after treatment with Hybrid Cooperative Complex (HCC) using standardized photography, clinical assessment, and validated rating scales. Ten healthy adult participants received two treatment sessions according to the Bio Aesthetic Points protocol, and outcomes were assessed at baseline and on Days 30, 60, 120, and 180. Visible improvement in facial pore size and skin texture was observed after treatment. Peak pore refinement was noted at Day 120 in most participants, while partial regression was observed in many cases by Day 180, although skin quality remained improved compared with baseline. HCC may be associated with visible improvement in facial pore size and skin quality in this pilot cohort. Changes in pore morphology may represent a practical clinical marker for estimating maintenance treatment timing, although larger controlled studies are needed.Keywords: Hyaluronic acid, Skin aging, Pores, Facial skin, Bioremodeling agentsSubject terms: Health care, Medical research Introduction Hybrid cooperative complex (HCC) is designed for individuals experiencing early to moderate signs of skin aging, including loss of elasticity, hydration, and firmness. With advancing age, declining levels of collagen, elastin, and endogenous hyaluronic acid (HA) contribute to structural and functional alterations in the dermis, resulting in compromised barrier function, dehydration, wrinkling, sagging, and enlargement of facial pores1. HCC represents an injectable bioremodeling agent consisting of high- and low-molecular-weight hyaluronic acid (H-HA and L-HA) in a stabilized hybrid cooperative complex. This formulation has been reported to improve skin hydration, tone, elasticity, and texture through dermal bioremodeling mechanisms2. Although the clinical effects of HCC on skin quality have been described, its specific impact on facial pore size, a highly visible and psychologically relevant aesthetic feature, has not been specifically investigated. Previous real-world clinical experience reported that HCC administered using the standardized Bio Aesthetic Points (BAP) technique promoted visible dermal bioremodeling, improved elasticity, and skin tone enhancement3. At the cellular level, Stellavato et al. demonstrated that hybrid cooperative complexes of hyaluronic acid may reactivate fibroblast proliferation and extracellular matrix turnover while maintaining low inflammatory signaling compared with crosslinked gels4. These findings provide a biological rationale for the potential dermal remodeling and pore-refining effects hypothesized in the current study. Moreover, Kim et al. reported that pore volume, rather than pore count, is most strongly correlated with visual assessment of skin pores, supporting the rationale for using pore morphology as a clinically relevant endpoint in aesthetic studies5. HCC differs from traditional fillers in that it is intended to promote pan-dermal remodeling and hydration rather than localized volumization. This distinction supports the design of the present investigation, which focuses on visible changes in pore morphology rather than filling effects6. This pilot study was not intended to evaluate general skin quality alone, but specifically to examine changes in facial pore morphology following HCC treatment. The study was inspired by clinical observations, with the central hypothesis that changes in pore size may serve as a practical, visible marker for determining the optimal timing of maintenance treatments. IBSA currently recommends a maintenance interval of 2–6 months after an initial two-treatment course spaced four weeks apart7. However, clinical experience suggests that pore morphology could help refine this interval based on individualized treatment response. This study therefore aimed to observe pore size evolution over 180 days as a preliminary investigation of facial pore size as a treatment endpoint for HCC. Methods Study design and participants This independent, prospective observational pilot study enrolled ten healthy adult participants (nine females and one male; age range, 32–52 years; mean age, 40.7 years) presenting with visible facial pores and early signs of facial skin aging. Exclusion criteria included aesthetic procedures within the preceding 6 months, active dermatologic disease, infection, pregnancy, or hypersensitivity to hyaluronic acid. No participants received any additional cosmetic treatment during the study period. Participant demographic characteristics are summarized in Table 1. Table 1Demographic characteristics of study participants.Patient IDAge, yearsSexP0142FemaleP0234FemaleP0337FemaleP0432MaleP0551FemaleP0647FemaleP0736FemaleP0844FemaleP0932FemaleP1052Female Demographic characteristics of study participants. All methods were carried out in accordance with relevant guidelines and regulations. The study protocol was approved by the Public Institutional Review Board of the Republic of Korea (Approval No. P01-202509-01-018). Written informed consent was obtained from all participants prior to inclusion in the study, including consent for the use of clinical photographs for publication purposes. Treatment protocol All participants received two sessions of HCC (IBSA Farmaceutici, Italy) administered using the Bio Aesthetic Points technique, with five standardized injection sites per hemiface: zygomatic prominence, nasal base, tragus region, chin, and mandibular angle. Each point received 0.2 mL of product at a superficial subcutaneous depth using a 29-gauge needle. The second session was performed 30 days after the first. All procedures were performed by the same experienced injector under aseptic conditions. No topical anesthesia was used, and all procedures were well tolerated without adverse events. Photography and clinical evaluation Standardized photographic documentation was obtained at baseline and on Days 30, 60, 120, and 180 using identical lighting, positioning, and camera settings. Facial pores were evaluated by direct clinical inspection and high-resolution photographic comparison, with particular attention to the malar and submalar regions. Outcome measures Pore size and global skin quality were evaluated using the Scientific Assessment Scale of Skin Quality (SASSQ)8. Aesthetic improvement was assessed using the Global Aesthetic Improvement Scale by both the investigator (GAIS-I) and the participants (GAIS-P). The pore grading criteria used for clinical evaluation are summarized in Table 2. Table 2Pore grading criteria used for clinical assessment.GradeClassificationDescription5Very large poresProminent, clearly visible pores with irregular surface texture; noticeable even at conversational distance4Large poresEasily visible pores, mainly concentrated in the T-zone and malar areas; mild irregularity of surface texture3Moderate poresVisible upon close inspection; overall skin texture moderately refined with mild unevenness2Small poresMinimally visible pores; smooth surface texture with good light reflection and uniformity1Very small or invisible poresPores virtually imperceptible; smooth, uniform skin texture with high surface regularity Pore grading criteria used for clinical assessment. Data analysis Because of the pilot nature of the study and small sample size, data were analyzed descriptively. Primary outcomes were changes in facial pore appearance and skin quality over time. Secondary outcomes included investigator- and patient-reported aesthetic improvement. Trends were evaluated across Days 0, 30, 60, 120, and 180 to determine the peak response period and the onset of regression in pore refinement. Results Pore size changes over time Day 30 All participants demonstrated visible reduction in facial pore prominence accompanied by improved skin texture and luminosity. Both clinical evaluation and standardized photographic comparison confirmed an early treatment response following the second HCC session. Day 120 Peak pore refinement was observed at Day 120 in nine of ten participants, based on standardized photography and SASSQ scoring. The skin exhibited maximum smoothness, minimized pore visibility, and enhanced uniformity of surface texture during this period. Representative standardized facial photographs illustrate visible pore reduction (Fig. 1), and mean facial pore size measurements before and after treatment demonstrate a corresponding decrease in pore dimensions (Fig. 2). Standardized facial photographs at baseline and post-treatment showing visible pore reduction following Hybrid Cooperative Complex treatment. Mean facial pore size measurements before and after treatment demonstrating reduction in pore dimensions. Day 180 By Day 180, although patients and clinicians continued to report a subjectively favorable overall appearance, photographic analysis revealed regression of peak pore refinement in most cases. Despite this decline from peak response, all participants maintained skin quality that appeared improved compared with baseline. One of the ten participants, as verified by high-resolution photography and SASSQ scoring, showed persistent peak pore refinement at Day 180. A summary of peak pore improvement and suggested maintenance timing is presented in Table 3. Table 3Summary of peak pore improvement and suggested maintenance timing. A supporting study website can be found at www.porestudy.com.Patient IDAge, yearsPeak pore improvement, daysRegression of peak response at Day 180Suggested maintenance timingP0142120MarkedBetween Day 120 and Day 180P0234120PartialBetween Day 120 and Day 180P0337180NoneDay 180 or laterP0432120MarkedBetween Day 120 and Day 180P0551120MarkedBetween Day 120 and Day 180P0647120MarkedBetween Day 120 and Day 180P0736120PartialBetween Day 120 and Day 180P0844120MarkedBetween Day 120 and Day 180P0932120MarkedBetween Day 120 and Day 180P1052120MarkedBetween Day 120 and Day 180 Summary of peak pore improvement and suggested maintenance timing. A supporting study website can be found at www.porestudy.com. Discussion Clinical relevance of pore size HCC treatment was associated with visible improvement in facial pore appearance, potentially through enhanced dermal hydration, improved dermal support, and extracellular matrix remodeling. The observed changes over follow-up suggest that pore morphology may reflect aspects of dermal remodeling status. These findings support the potential role of pore assessment as a practical clinical marker when considering maintenance treatment timing. This study has several limitations, including the small sample size, the absence of a control group, and the descriptive nature of the analysis. In addition, reliance on photographic and clinical assessment may introduce observer bias, and no instrumental pore-measurement system was used. Larger controlled studies using objective imaging and quantitative assessment tools are needed to validate these preliminary findings. The observed reduction in facial pore prominence following HCC treatment may be explained by multi-layered dermal remodeling mechanisms, as described in previous studies of hybrid complexes of high- and low-molecular-weight hyaluronic acid9. Potential mechanisms include fibroblast activation, collagen stimulation, elastin remodeling, enhanced dermal hydration, increased tissue turgor, and extracellular matrix reorganization. These mechanisms are further supported by ex vivo and in vitro evidence from Stellavato et al., who showed that hybrid cooperative complexes may reactivate quiescent fibroblasts and promote extracellular matrix renewal4. Similarly, prior clinical experience with the BAP injection technique has reported improvement in skin turgor and smoothness, aligning with the present study’s findings of progressive pore refinement and improved surface uniformity3. Taken together, these findings suggest that the effect of HCC may extend beyond hydration to include cellular reactivation, extracellular matrix remodeling, and surface-level texture improvement that may be reflected in pore morphology. However, these mechanisms remain inferential in the present study. Future studies using high-frequency ultrasound, optical coherence tomography, VISIA analysis, PRIMOS 3D surface analysis, or biopsy-based morphometric assessment are warranted to confirm the cellular and extracellular matrix-level changes underlying pore size modulation. The correlation between pore size and perceived skin quality reported by Kim et al. also supports the clinical relevance of this outcome measure. Because pore volume has been shown to correlate strongly with visual assessment, reduction in pore prominence may represent both a biologically relevant and patient-perceived aesthetic endpoint5. Timing of peak effect and decline This study identified Day 120 as the peak improvement interval for nine of ten participants, with one participant exhibiting continued improvement through Day 180. By the end of the 180-day observation period, nine of ten participants showed some degree of regression from peak pore refinement, despite maintaining a clinically favorable appearance and patient-reported satisfaction. These findings suggest that HCC-associated pore refinement may follow a temporal pattern characterized by progressive improvement, peak response, and subsequent partial decline. Toward pore-based maintenance timing The observed relationship between visible pore regression and declining treatment effect suggests that pore morphology may have value as a practical, patient-observable clinical marker for estimating maintenance treatment timing. Rather than adhering strictly to calendar-based intervals, clinicians may consider re-treatment when patients or practitioners notice progressive pore re-enlargement, supported by standardized photographic assessment. While this pilot cohort was not powered to establish definitive or age-stratified recommendations, the results underscore the potential of pore-based evaluation as a personalized, outcome-driven tool for aesthetic maintenance planning. Future randomized controlled trials with larger cohorts, comparator groups, objective measurement devices, and formal statistical testing are required to confirm these preliminary observations. Conclusion This pilot study suggests that facial pore size may visibly improve following HCC treatment, with the greatest apparent effect observed around Day 120 in most participants. By Day 180, photographic evaluation indicated regression of peak pore refinement in many participants, suggesting that visible pore morphology may be useful as a practical clinical indicator when considering maintenance treatment timing. These findings should be interpreted cautiously. The small sample size, absence of a control group, descriptive analysis, and lack of instrumental pore measurements limit generalizability and preclude definitive causal conclusions. Future research should focus on the 120- to 180-day interval to better characterize the transition between peak response and decline and to refine individualized maintenance strategies. Objective imaging techniques, such as high-frequency ultrasound, VISIA, or PRIMOS 3D surface analysis, may help clarify the dermal and extracellular matrix-level mechanisms underlying pore refinement. Larger randomized controlled studies are required to confirm these preliminary observations. Acknowledgements The authors express sincere gratitude to all participating patients for their cooperation and commitment. Author contributions All authors have reviewed and approved the article for submission. Conceptualization: Erik Koppert, Roya Zarmehrzamin, Kyu-Ho Yi Writing—Original Draft Preparation: Erik Koppert, Roya Zarmehrzamin, Kyu-Ho Yi Writing—Review & Editing: Suyeon Lee, Kyu-Ho Yi Visualization: Erik Koppert, Roya Zarmehrzamin, Suyeon Lee, Kyu-Ho Yi Supervision: Kyu-Ho Yi. Funding This investigation received no external or commercial funding. Data availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no conflicts of interest related to this study. Ethical approval The study protocol was approved by an independent institutional ethics committee (Public Institutional Review Board of the Republic of Korea). All participants provided written informed consent prior to inclusion in the study, including consent for the use of clinical photographs for publication purposes. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.